CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies

• Published in: Cell reports (Cambridge) Vol. 29; no. 11; pp. 3405 - 3420.e5
• Main Authors: Feng, William W., Wilkins, Owen, Bang, Scott, Ung, Matthew, Li, Jiaqi, An, Jennifer, del Genio, Carmen, Canfield, Kaleigh, DiRenzo, James, Wells, Wendy, Gaur, Arti, Robey, R. Brooks, Guo, Jessie Yanxiang, Powles, Ryan L., Sotiriou, Christos, Pusztai, Lajos, Febbraio, Maria, Cheng, Chao, Kinlaw, William B., Kurokawa, Manabu
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.12.2019; Elsevier
• Subjects: AKT; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; CD36 Antigens - genetics; CD36 Antigens - metabolism; Cell Line, Tumor; drug resistance; Drug Resistance, Neoplasm; ERK; FASN; Fatty Acids - metabolism; Female; HER2; Humans; Lapatinib - pharmacology; Lapatinib - therapeutic use; lipid metabolism; MAPK; Mice; Mice, Inbred NOD; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Receptor, ErbB-2 - antagonists & inhibitors; tyrosine kinase; FASN; tyrosine kinase; lipid metabolism; AKT; drug resistance; HER2; MAPK; ERK
• ISSN: 2211-1247; 2211-1247
• DOI: 10.1016/j.celrep.2019.11.008

Although it is established that fatty acid (FA) synthesis supports anabolic growth in cancer, the role of exogenous FA uptake remains elusive. Here we show that, during acquisition of resistance to HER2 inhibition, metabolic rewiring of breast cancer cells favors reliance on exogenous FA uptake over de novo FA synthesis. Through cDNA microarray analysis, we identify the FA transporter CD36 as a critical gene upregulated in cells with acquired resistance to the HER2 inhibitor lapatinib. Accordingly, resistant cells exhibit increased exogenous FA uptake and metabolic plasticity. Genetic or pharmacological inhibition of CD36 suppresses the growth of lapatinib-resistant but not lapatinib-sensitive cells in vitro and in vivo. Deletion of Cd36 in mammary tissues of MMTV-neu mice significantly attenuates tumorigenesis. In breast cancer patients, CD36 expression increases following anti-HER2 therapy, which correlates with a poor prognosis. Our results define CD36-mediated metabolic rewiring as an essential survival mechanism in HER2-positive breast cancer. [Display omitted] •Lapatinib-resistant breast cancer cells upregulate CD36 expression for survival•Targeting CD36 re-sensitizes lapatinib-resistant cells to HER2-inhibition•Deletion of Cd36 significantly attenuates MMTV-neu-driven mammary tumor growth•CD36 is induced by HER2-targeted therapy and predicts poor clinical prognosis The functional significance of lipid metabolism in cancer cells is not fully understood. Feng et al. show that the fatty acid transporter CD36 is essential for survival of breast cancer cells during anti-HER2 therapy, highlighting the role of lipid metabolism in acquired resistance to targeted therapy.